Meridian Bioscience (VIVO) Completes Acquisition of Magellan Biosciences
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises in broad rebound; yields push markets towards weekly declines
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Canaccord Genuity Remains Sidelined Following Meridian Bioscience's (VIVO) Announced Magellan Diagnostics Acquisition
March 28, 2016 10:17 AM EDTCanaccord Genuity reiterated a Hold rating on Meridian Biosciences (NASDAQ: VIVO), and raised the price target to $19.00 (from $18.00), following the company's announced acquisition of Magellan Diagnostics. The acquisition marks VIVO's first material acquisition in nearly 6 years. Boston-based Magellan Diagnostics offers the only rapid (3-minute),... More
